Kenya - English - Pharmacy and Poisons Board

beacon medicare limited 9/b/2, toyenbee circular road, motijheel, - tofacitinib citrate inn - film-coated tablet - tofacitinib 5mg - tofacitinib

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; poloxamer; magnesium stearate; hyprolose; purified water; povidone; titanium dioxide; macrogol 8000; hypromellose; iron oxide red; macrogol 400 - atovaquopro lupin is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults and children greater than or equal to 11 kg.,? treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atovaquone, quantity: 62.5 mg; proguanil hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: povidone; poloxamer; colloidal anhydrous silica; purified water; magnesium stearate; hyprolose; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; macrogol 8000; hypromellose; iron oxide red; macrogol 400 - atovaquopro lupin is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults and children greater than or equal to 11 kg.,? treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atovaquone, quantity: 250 mg; proguanil hydrochloride, quantity: 100 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; purified water; poloxamer; povidone; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; macrogol 8000; hypromellose; iron oxide red; macrogol 400 - atovaquopro lupin is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults and children greater than or equal to 11 kg.,? treatment of plasmodium falciparum malaria in adults and children aged 3 years or older.

Canada - English - Health Canada

auro pharma inc - tofacitinib (tofacitinib citrate) - tablet - 10mg - tofacitinib (tofacitinib citrate) 10mg

Canada - English - Health Canada

auro pharma inc - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

Canada - English - Health Canada

pharmascience inc - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

Canada - English - Health Canada

apotex inc - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

Canada - English - Health Canada

apotex inc - tofacitinib (tofacitinib citrate) - tablet - 10mg - tofacitinib (tofacitinib citrate) 10mg

United States - English - NLM (National Library of Medicine)

vistapharm, llc - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt) - atovaquone oral suspension is indicated for the prevention of pneumocystis jirovecii pneumonia (pcp) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (tmp-smx). atovaquone oral suspension is indicated for the acute oral treatment of mild-to-moderate pcp in adults and adolescents (aged 13 years and older) who cannot tolerate tmp-smx. clinical experience with atovaquone oral suspension for the treatment of pcp has been limited to subjects with mild-to-moderate pcp (alveolar-arterial oxygen diffusion gradient [(a-a)do2 ] ≤45 mm hg). treatment of more severe episodes of pcp with atovaquone oral suspension, usp has not been studied. the efficacy of atovaquone in subjects who are failing therapy with tmp-smx has also not been studied. atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquon